(TAK) Takeda Pharmaceutical - Overview

Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NYSE (USA) | Market Cap: 57.118m USD | Total Return: 31.4% in 12m

Rare Diseases, Oncology, Immunology, Gastroenterology, Plasma Therapies
Total Rating 50
Safety 66
Buy Signal -0.18
Drug Manufacturers - Specialty & Generic
Industry Rotation: -2.3
Market Cap: 57.1B
Avg Turnover: 51.7M USD
ATR: 1.90%
Peers RS (IBD): 50.6
Risk 5d forecast
Volatility21.7%
Rel. Tail Risk-0.43%
Reward TTM
Sharpe Ratio1.19
Alpha27.06
Character TTM
Beta0.069
Beta Downside0.353
Drawdowns 3y
Max DD23.25%
CAGR/Max DD0.30
EPS (Earnings per Share) EPS (Earnings per Share) of TAK over the last years for every Quarter: "2021-03": 63.08, "2021-06": 64, "2021-09": -5.13, "2021-12": 0.1605, "2022-03": -0.0271, "2022-06": 33.97, "2022-09": 20.03, "2022-12": 0.2927, "2023-03": 0.074, "2023-06": 28.76, "2023-09": -15.5, "2023-12": 33.79, "2024-03": -0.0065, "2024-06": 0.1923, "2024-09": 29.07, "2024-12": 0.0478, "2025-03": -0.2276, "2025-06": 151, "2025-09": -0.0253, "2025-12": 0.2099,
EPS CAGR: 0.41%
EPS Trend: -7.7%
Last SUE: 0.00
Qual. Beats: 0
Revenue Revenue of TAK over the last years for every Quarter: 2021-03: 770274, 2021-06: 949603, 2021-09: 844819, 2021-12: 901294, 2022-03: 873289, 2022-06: 972465, 2022-09: 1002307, 2022-12: 1096551, 2023-03: 956156, 2023-06: 1058618, 2023-09: 1043089, 2023-12: 1111186, 2024-03: 1050869, 2024-06: 1207990, 2024-09: 1176038, 2024-12: 1144124, 2025-03: 1053400, 2025-06: 1106685, 2025-09: 1112796, 2025-12: 1213211.32,
Rev. CAGR: 9.16%
Rev. Trend: 75.9%
Last SUE: 0.01
Qual. Beats: 0

Warnings

P/E ratio 82.2

Tailwinds

No distinct edge detected

Description: TAK Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited researches, develops, manufactures, markets, and out-licenses pharmaceutical products globally. The company operates in the pharmaceutical sector, a research-intensive industry characterized by long development cycles and significant regulatory hurdles.

Takeda focuses on gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. Its business model involves both internal product development and strategic collaborations, including in-licensing, out-licensing, and research partnerships with other biotechnology and pharmaceutical companies. This approach is common in the pharmaceutical industry to diversify pipelines and share development costs.

Key brands include Entyvio, Takecab/Vocinti, Takhzyro, Ninlaro, and Velcade. The company maintains an extensive network of collaborations and licensing agreements, such as those with BioMarin, GlaxoSmithKline, Neurocrine Biosciences, and Arrowhead Pharmaceuticals Inc. To gain deeper insights into Takeda’s strategic partnerships and pipeline, further research on ValueRay is recommended.

Headlines to Watch Out For
  • Entyvio sales growth drives gastroenterology revenue
  • Rare disease pipeline advancements boost future outlook
  • Plasma-derived therapies face supply chain risks
  • Oncology drug sales impacted by generic competition
  • Neuroscience portfolio expansion increases market share
Piotroski VR‑10 (Strict) 3.5
Net Income: 114.75b TTM > 0 and > 6% of Revenue
FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.13 > 1.0
NWC/Revenue: 11.29% < 20% (prev 14.33%; Δ -3.04% < -1%)
CFO/TA 0.08 > 3% & CFO 1175.85b > Net Income 114.75b
Net Debt (4201.25b) to EBITDA (1393.38b): 3.02 < 3
Current Ratio: 1.19 > 1.5 & < 3
Outstanding Shares: last quarter (3.20b) vs 12m ago 1.10% < -2%
Gross Margin: 62.11% > 18% (prev 0.65%; Δ 6.15k% > 0.5%)
Asset Turnover: 29.39% > 50% (prev 30.31%; Δ -0.92% > 0%)
Interest Coverage Ratio: 1.97 > 6 (EBITDA TTM 1393.38b / Interest Expense TTM 316.48b)
Altman Z'' 1.52
A: 0.03 (Total Current Assets 3118.57b - Total Current Liabilities 2611.96b) / Total Assets 15419.29b
B: 0.07 (Retained Earnings 1096.41b / Total Assets 15419.29b)
C: 0.04 (EBIT TTM 622.74b / Avg Total Assets 15263.07b)
D: 0.77 (Book Value of Equity 5944.22b / Total Liabilities 7769.98b)
Altman-Z'' Score: 1.52 = BB
Beneish M -3.04
DSRI: 1.05 (Receivables 758.44b/735.06b, Revenue 4486.09b/4579.02b)
GMI: 1.05 (GM 62.11% / 65.38%)
AQI: 0.97 (AQ_t 0.66 / AQ_t-1 0.68)
SGI: 0.98 (Revenue 4486.09b / 4579.02b)
TATA: -0.07 (NI 114.75b - CFO 1175.85b) / TA 15419.29b)
Beneish M-Score: -3.04 (Cap -4..+1) = AA
What is the price of TAK shares? As of April 13, 2026, the stock is trading at USD 18.08 with a total of 2,684,704 shares traded.
Over the past week, the price has changed by -0.77%, over one month by +3.43%, over three months by +13.04% and over the past year by +31.43%.
Is TAK a buy, sell or hold? Takeda Pharmaceutical has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy TAK.
  • StrongBuy: 3
  • Buy: 0
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the TAK price?
Analysts Target Price 20.6 13.8%
Takeda Pharmaceutical (TAK) - Fundamental Data Overview as of 13 April 2026
Market Cap JPY = 9062.35b (57.12b USD * 158.6595 USD.JPY)
P/E Trailing = 82.1818
P/E Forward = 12.5628
P/S = 0.0128
P/B = 1.1858
P/EG = 0.3915
Revenue TTM = 4486.09b JPY
EBIT TTM = 622.74b JPY
EBITDA TTM = 1393.38b JPY
Long Term Debt = 4270.17b JPY (from longTermDebt, last quarter)
Short Term Debt = 583.55b JPY (from shortTermDebt, last quarter)
Debt = 4856.63b JPY (from shortLongTermDebtTotal, last quarter)
Net Debt = 4201.25b JPY (from netDebt column, last quarter)
Enterprise Value = 13264.04b JPY (9062.35b + Debt 4856.63b - CCE 654.94b)
Interest Coverage Ratio = 1.97 (Ebit TTM 622.74b / Interest Expense TTM 316.48b)
EV/FCF = 13.87x (Enterprise Value 13264.04b / FCF TTM 956.59b)
FCF Yield = 7.21% (FCF TTM 956.59b / Enterprise Value 13264.04b)
FCF Margin = 21.32% (FCF TTM 956.59b / Revenue TTM 4486.09b)
Net Margin = 2.56% (Net Income TTM 114.75b / Revenue TTM 4486.09b)
Gross Margin = 62.11% ((Revenue TTM 4486.09b - Cost of Revenue TTM 1699.70b) / Revenue TTM)
Gross Margin QoQ = 54.43% (prev 65.85%)
Tobins Q-Ratio = 0.86 (Enterprise Value 13264.04b / Total Assets 15419.29b)
Interest Expense / Debt = 2.59% (Interest Expense 125.86b / Debt 4856.63b)
Taxrate = 22.51% (30.67b / 136.28b)
NOPAT = 482.57b (EBIT 622.74b * (1 - 22.51%))
Current Ratio = 1.19 (Total Current Assets 3118.57b / Total Current Liabilities 2611.96b)
Debt / Equity = 0.64 (Debt 4856.63b / totalStockholderEquity, last quarter 7648.16b)
Debt / EBITDA = 3.02 (Net Debt 4201.25b / EBITDA 1393.38b)
Debt / FCF = 4.39 (Net Debt 4201.25b / FCF TTM 956.59b)
Total Stockholder Equity = 7144.80b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.75% (Net Income 114.75b / Total Assets 15419.29b)
RoE = 1.61% (Net Income TTM 114.75b / Total Stockholder Equity 7144.80b)
RoCE = 5.46% (EBIT 622.74b / Capital Employed (Equity 7144.80b + L.T.Debt 4270.17b))
RoIC = 4.10% (NOPAT 482.57b / Invested Capital 11773.46b)
WACC = 4.76% (E(9062.35b)/V(13918.98b) * Re(6.23%) + D(4856.63b)/V(13918.98b) * Rd(2.59%) * (1-Tc(0.23)))
Discount Rate = 6.23% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 33.33 | Cagr: 0.55%
[DCF] Terminal Value 85.40% ; FCFF base≈940.79b ; Y1≈860.63b ; Y5≈764.08b
[DCF] Fair Price = 5.94k (EV 22954.47b - Net Debt 4201.25b = Equity 18753.22b / Shares 3.16b; r=6.0% [WACC]; 5y FCF grow -10.67% → 3.0% )
EPS Correlation: -7.72 | EPS CAGR: 0.41% | SUE: -0.00 | # QB: 0
Revenue Correlation: 75.85 | Revenue CAGR: 9.16% | SUE: 0.01 | # QB: 0
EPS next Year (2027-03-31): EPS=94.98 | Chg7d=-14.831 | Chg30d=-27.244 | Revisions Net=-1 | Growth EPS=+93.0% | Growth Revenue=+1.2%
External Resources
Dataroma Stockcircle